ArticlePloS one2012
Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-κB and upregulation of IL-1Ra in melanoma model.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Modulating tumor mechanics and vascular barriers to enhance chemotherapy efficacy in pancreatic tumors and melanoma.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- CCR5 deficiency: Decreased neuronal resilience to oxidative stress and increased risk of vascular dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Review
- EphA2 Promotes the Development of Cervical Cancer through the CXCL11/PD-L1 Pathway.Journal of oncology · 2022Article
- Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician.Cancers · 2021Review
- 7,8-Dihydroxyflavone improves neuropathological changes in the brain of Tg26 mice, a model for HIV-associated neurocognitive disorder.Scientific reports · 2021Article
- Evaluating the Association betweenIranian journal of public health · 2021Article
- Chemokines and chemokine receptors: A new strategy for breast cancer therapy.Cancer medicine · 2020Review
- CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma.Journal for immunotherapy of cancer · 2020Article
- Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers.Cancers · 2020Review
- Chemokines and Chemokine Receptors: Orchestrating Tumor Metastasization.International journal of molecular sciences · 2018Review
- CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma.Cancer immunology, immunotherapy : CII · 2017Review
- CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.Inflammation · 2015Article
- The frequency of CCR5 promoter polymorphisms and CCR5 Δ 32 mutation in Iranian populations.Iranian journal of basic medical sciences · 2015Review
- The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer.British journal of cancer · 2015Article
- Bringing Down Cancer Aircraft: Searching for Essential Hypomutated Proteins in Skin Melanoma.PloS one · 2015Article
- Chemokines in cancer.Cancer immunology research · 2014Review
- C-C chemokine receptor 5 on pulmonary mesenchymal cells promotes experimental metastasis via the induction of erythroid differentiation regulator 1.Molecular cancer research : MCR · 2014Article
- The inflammatory chemokine CCL5 and cancer progression.Mediators of inflammation · 2014Review
- Is the CCR5 Δ 32 mutation associated with immune system-related diseases?Inflammation · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the relevance of C-C chemokine receptor type 5 (CCR5) expression and tumor development, we compared melanoma growth in CCR5 knockout (CCR5(-/-)) mice and wild type (CCR5(+/+)) mice. CCR5(-/-) mice showed reduced tumor volume, tumor weight, and increased survival rate when compared to CCR5(+/+) mice. We investigated the activation of NF-κB since it is an implicated transcription factor in the regulation of genes involving cell growth, apoptosis, and tumor growth. Significant inhibition of DNA binding activity of NF-κB, and translocation of p50 and p65 into the nucleus through the inhibition of phosphorylation of IκB was found in the melanoma tissues of CCR5(-/-) mice compared to melanoma tissues of CCR5(+/+) mice. NF-κB target apoptotic protein expression, such as cleaved caspase-3, cleaved PARP, and Bax, was elevated, whereas the survival protein expression levels, such as Bcl-2, C-IAP1, was decreased in the melanoma tissues of CCR5(-/-) mice. Interestingly, we found that the level of IL-1Ra, a tumor growth suppressive cytokine, was significantly elevated in tumor tissue and spleen of CCR5(-/-) mice compared to the level in CCR5(+/+) mice. Moreover, infiltration of CD8(+) cytotoxic T cell and CD57(+) natural killer cells was significantly increased in melanoma tumor and spleen tissue of CCR5(-/-) mice compared to that of CCR5(+/+) mice. Therefore, these results showed that CCR5 deficiency caused apoptotic cell death of melanoma through inhibition of NF-κB and upregulation of IL-1Ra.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.